


# HIV Prevention Research, Development and Implementation Pipeline in 2020—and Beyond

The graphic below shows the wide range of HIV prevention and multipurpose prevention products (MPTs) available and in the pipeline. For a look at the timelines for when efficacy trials will have results, see Figure 13. Products that are “in development” are, for the most part, many years away from regulatory consideration and wide-scale introduction. The exception: combined oral PrEP and oral contraceptives, which could be ready in two to three years, at least five years before the next MPT might come to market.



## DEVELOPMENT TIMELINE (as of November 2019)

- Initial regulatory opinion on dapivirine ring in 2020; possible to market by 2021.
- Efficacy trial of F/TAF for cisgender women in South Africa set to begin in 2020.
- AMP results possibly released in 2020.
- PrEPvacc begins enrollment in 2020.
- CAB-LA results in 2022; possible to market by 2023/4.
- ALVAC results in 2021-22; possible licensure in South Africa.
- Ad26 results in 2021-23; possible licensure of “global vaccine”.
- Monthly pill in Phase III in 2021.
- Implants going into Phase II/III in 2021 preceded by decisions about which implant and which active drug.
- Combo bNABs in Phase II/III in 2021 preceded by decisions about which combinations.
- Multipurpose ring in Phase III in 2022.

\* Efficacy trials not required; bioequivalency of the two approved products when dosed together may be all that is required.

Additional information on trials and products in development available at [www.avac.org/prxd](http://www.avac.org/prxd).